These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43 related articles for article (PubMed ID: 24103731)
1. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway. Mitsiades CS J Clin Oncol; 2015 Mar; 33(7):782-5. PubMed ID: 25605842 [No Abstract] [Full Text] [Related]
2. Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons. Palanca A; Casafont I; Berciano MT; Lafarga M Cell Mol Life Sci; 2014 May; 71(10):1961-75. PubMed ID: 24061536 [TBL] [Abstract][Full Text] [Related]
3. The spleen is the major source of antidonor antibody-secreting cells in murine heart allograft recipients. Sicard A; Phares TW; Yu H; Fan R; Baldwin WM; Fairchild RL; Valujskikh A Am J Transplant; 2012 Jul; 12(7):1708-19. PubMed ID: 22420367 [TBL] [Abstract][Full Text] [Related]
4. Cold Storage Followed by Transplantation Induces Immunoproteasome in Rat Kidney Allografts: Inhibition of Immunoproteasome Does Not Improve Function. Bhattarai D; Lee SO; Joshi N; Jun SR; Lo S; Jiang L; Gokden N; Parajuli N Kidney360; 2024 May; 5(5):743-752. PubMed ID: 38303110 [TBL] [Abstract][Full Text] [Related]
5. Clinical Relevance of Isoagglutinin Rebound in Adult ABO-Incompatible Living Donor Liver Transplantation. Lee WC; Lee CF; Wu TH; Hung HC; Lee JC; Wang YC; Cheng CH; Wu TJ; Chou HS; Chan KM J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945772 [TBL] [Abstract][Full Text] [Related]
6. Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model. Natarajan P; Liu J; Santhanakrishnan M; Gibb DR; Slater LM; Hendrickson JE Transfusion; 2017 Jan; 57(1):82-92. PubMed ID: 27734515 [TBL] [Abstract][Full Text] [Related]
7. Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney Transplantation. Jeong JC; Jambaldorj E; Kwon HY; Kim MG; Im HJ; Jeon HJ; In JW; Han M; Koo TY; Chung J; Song EY; Ahn C; Yang J Medicine (Baltimore); 2016 Feb; 95(5):e2635. PubMed ID: 26844479 [TBL] [Abstract][Full Text] [Related]
8. The state of therapy for removal of alloantibody producing plasma cells in transplantation. Everly MJ; Terasaki PI Semin Immunol; 2012 Apr; 24(2):143-7. PubMed ID: 22153981 [TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition for antibody-mediated rejection. Everly JJ; Walsh RC; Alloway RR; Woodle ES Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989 [TBL] [Abstract][Full Text] [Related]
10. Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice. Redfield RR; Lou Y; Rodriguez E; Rostami S; Parsons RF; Noorchashm H; Naji A; Abt PL Transpl Immunol; 2013 Dec; 29(1-4):11-6. PubMed ID: 24103731 [TBL] [Abstract][Full Text] [Related]
11. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Diwan TS; Raghavaiah S; Burns JM; Kremers WK; Gloor JM; Stegall MD Transplantation; 2011 Mar; 91(5):536-41. PubMed ID: 21283064 [TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor treatment of antibody-mediated allograft rejection. Woodle ES; Alloway RR; Girnita A Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709 [TBL] [Abstract][Full Text] [Related]
13. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130 [TBL] [Abstract][Full Text] [Related]